Antibe Therapeutics Announces No Material Change
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any
undisclosed material change in the Company’s activities that would account for recent market activity. As previously disclosed in
its February 26th, 2018 press release, the Company anticipates being in a position to report top-line results of the
Phase 2b clinical trial of its lead drug, ATB-346, during the week of March 19th, 2018.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent
global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products
servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of
knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries,
operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing
and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties
that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news
release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are
not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all,
its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical
device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update
the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable
law.
Antibe Therapeutics Inc.
Dan Legault, (416) 473 4095
Chief Executive Officer
dan.legault@antibethera.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005948/en/